University of Alberta Hospital, Royal Alexandra Hospital
Welcome,         Profile    Billing    Logout  
 24 Trials 
2 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wright, Erin
SPRINKLE, NCT05309668 / 2020-005608-20: Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

Hourglass Jul 2024 - Dec 2024 : Results from SPRINKLE trial in children aged 1 to 6 years with NF1 related symptomatic, inoperable plexiform neurofibromas
Active, not recruiting
1/2
36
Europe, Japan, US, RoW
Selumetinib granule formulation, Selumetinib capsule formulation
AstraZeneca, Merck Sharp & Dohme LLC
Neurofibromatosis Type 1
04/24
04/28
NCT04238819: A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Active, not recruiting
1/2
117
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Irinotecan, Temozolomide, Dinutuximab, GM-CSF
Eli Lilly and Company
Relapsed Solid Tumor, Refractory Solid Tumor
03/24
04/25

Download Options